first
truetodetail
draw
struggl
axon
injuri
site
central
peripher
nerv
system
cn
pn
prepar
santiago
ramon
cajal
sinc
plethora
public
gener
attempt
comprehend
event
occur
cn
pn
injuri
time
larg
number
gene
protein
substanc
discov
collect
involv
abl
influenc
process
although
consider
improv
observ
regard
promis
candid
satisfi
result
treat
insult
cn
achiev
earli
respons
prevent
complic
acceler
recoveri
necessari
medic
cn
trauma
henc
avail
safe
easi
administ
therapeut
longawait
pursuit
treatment
even
cure
paralysi
continu
knockdown
agent
deoxyribozym
might
relev
regard
abil
act
enzym
bind
target
mrna
via
sequencespecif
bindingarm
cleav
target
via
catalyt
loop
structur
releas
digest
fragment
deoxyribozym
abl
bind
cleav
mrna
molecul
gene
deoxyribozym
overlook
last
year
harbor
great
therapeut
potenti
review
summar
select
process
deoxyribozym
develop
digest
mechan
requir
modif
length
sequencespecif
bind
arm
exist
knowledg
uptak
mechan
nucleicacidbas
molecul
cell
therapeut
applic
furthermor
comprehend
multifactotri
complex
mechan
occur
cn
trauma
review
also
summar
result
obtain
via
bioinformat
approach
deoxyribozym
singlestrand
dna
molecul
also
call
dna
enzym
dnazym
develop
breaker
joyc
santoro
joyc
use
systemat
evolut
ligand
exponenti
enrich
selex
fig
idea
develop
catalyt
dna
molecul
aros
rna
form
ribozym
abl
function
enzym
howev
simpl
translat
ribozym
sequenc
dna
replac
u
show
satisfi
result
detect
cleavag
target
mrna
occur
consequ
random
search
dna
sequenc
undertaken
use
selex
first
attempt
result
deoxyribozym
one
call
fig
b
cleav
phosphodiest
immedi
singl
ribonucleotid
embed
within
dna
substrat
fig
b
either
unabl
cleav
extend
rna
sequenc
replac
origin
dna
substrat
breaker
joyc
cleav
significantli
lower
rate
roth
breaker
next
attempt
carri
anoth
group
faulhamm
famulok
abl
identifi
deoxyribozym
spite
never
part
select
process
howev
deoxyribozym
unabl
cleav
within
extend
rna
sequenc
tackl
problem
santoro
joyc
gener
librari
approxim
singlestrand
dna
molecul
contain
biotin
moieti
follow
direct
short
oligodeoxynucleotid
spacer
target
ribonucleotid
rna
sequenc
cleav
random
deoxynucleotid
potenti
dna
enzym
random
region
surround
fixedsequ
deoxynucleotid
site
primer
hybrid
fig
c
molecul
appli
streptavidinco
solid
support
elut
solut
contain
mm
ph
molecul
cleav
rna
phosphoest
within
small
fraction
bound
molecul
releas
cleavag
product
eluat
releas
materi
recov
amplifi
polymeras
chain
reaction
pcr
pcr
pool
subject
gener
progeni
popul
dna
molecul
enrich
desir
popul
two
side
target
rna
sequenc
emerg
hotspot
cleavag
one
amplif
round
round
eighth
tenth
round
enrich
sequenc
clone
analyz
detail
total
clone
two
motif
fig
show
extens
watsoncrick
pair
target
rna
sequenc
locat
upstream
downstream
cleavag
site
name
two
deoxyribozym
coin
base
clone
cycl
vitro
select
process
catalyt
core
enzym
locat
two
substratebind
arm
contain
deoxynucleotid
respect
santoro
joyc
deoxyribozym
requir
dival
metal
ion
cleav
target
mrna
dna
enzym
contain
short
intern
stemloop
base
pair
least
two
gc
follow
unpair
region
nucleotid
contrast
dna
enzym
contain
unpair
loop
structur
eighth
nucleotid
posit
catalyt
core
either
c
highest
level
activ
provid
posit
apart
entir
loop
sequenc
intoler
chang
sugimoto
et
al
li
et
al
around
time
geyer
sen
identifi
rnacleav
deoxyribozym
work
independ
dival
metal
ion
abl
increas
rna
cleavag
monoval
ion
na
effect
cofactor
laboratori
feldman
sen
publish
deoxyribozym
prefer
sever
unpair
ribonucleotid
cleavag
site
newli
form
bipartit
deoxyribozym
fig
howev
absolut
requir
certain
dival
metal
salt
cleavag
roth
breaker
present
sever
histidinedepend
deoxyribozym
fig
ensur
absenc
dival
ion
select
process
edta
ad
requir
addit
k
imidazol
group
histidin
imidazol
group
like
acceler
cleavag
reaction
facilit
deproton
target
site
hydroxyl
group
latest
identif
deoxyribozym
broad
ph
toler
vitro
select
perform
xiao
et
al
deoxyribozym
one
sever
deoxyribozym
variant
enhanc
hydrolysi
uncatalyz
po
bond
rate
deoxyribozym
compar
activ
presenc
mixtur
mm
mm
ph
wherea
essenti
inact
mm
use
contrast
show
threefold
reduct
condit
one
factor
influenc
dissoci
rate
deoxyribozym
substrat
length
bind
arm
form
watsoncrick
base
pair
target
mrna
upstream
downstream
cleavag
site
earli
studi
sun
colleagu
show
deoxyribozym
sequenc
length
nucleotid
arm
arm
left
site
arm
ii
right
side
deoxyribozym
fig
perform
best
use
target
sequenc
human
papilloma
viru
hpv
wherea
deoxyribozym
arm
arm
ii
length
combin
perform
better
target
sequenc
cmyc
arm
length
deoxyribozym
hpv
reduc
strong
reduct
observ
wherea
chang
led
either
almost
undetect
cleavag
activ
hpv
strong
reduct
cmyc
cairn
et
al
notabl
bind
arm
long
dissoci
target
mrna
occur
thu
antisens
effect
observ
design
deoxyribozym
length
hybrid
arm
nucleotid
side
santoro
joyc
secur
cleavag
releas
shown
choi
et
al
arm
iarmii
length
ratio
yang
et
al
ratio
digest
deoxyribozym
requir
dinucleotid
combin
gc
gu
ac
au
target
mrna
sequenc
wherea
digest
deoxyribozym
sole
ag
suffici
fig
henc
deoxyribozym
broader
target
rang
substrat
requir
unpair
purin
g
pair
pyrimidin
c
u
ideal
site
test
longfold
mrna
greater
likelihood
find
highli
access
cleavabl
site
cairn
et
al
best
effici
substrat
cleavag
observ
target
site
consist
u
deoxyribozym
santoro
joyc
descend
order
follow
rarc
increas
activ
particular
last
two
dinucleotid
combin
gc
ac
substitut
dg
deoxyinosin
di
effici
thu
three
hydrogen
bond
rcdg
convert
two
hydrogen
bond
rcdi
improv
biolog
activ
deoxyribozym
cairn
et
al
final
cleavag
occur
side
singl
unpair
ribonucleotid
prefer
purin
follow
pair
pyrimidin
within
allrna
substrat
santoro
joyc
herebi
deoxyribozym
bend
substrat
away
cleavag
point
expos
reactiv
site
buckl
catalyt
core
kenward
dorfman
rna
cleavag
catalyz
transesterif
oxygen
mo
metal
ion
oh
group
serv
nucleophil
attack
phosphoru
center
adjac
phosphoest
linkag
reaction
word
dival
cation
serv
lewi
base
metal
hydroxid
gener
endproduct
phosphat
rna
termini
fig
afterward
catalyt
core
deoxyribozym
unwind
complex
extend
one
nonbridg
oxygen
atom
phosphodiest
bond
replac
sulfur
introduct
small
number
phosphorothio
oligonucleotid
pto
eg
three
end
render
greater
stabil
deoxyribozym
without
influenc
efficaci
sioud
leirdal
studi
sun
et
al
introduct
phosphorothio
ps
bond
hybrid
arm
pyrimidin
residu
catalyt
core
select
inhibit
human
glioma
cell
growth
howev
schubert
et
al
observ
deceler
cleavag
rate
onefifth
ps
linkag
introduc
throughout
entir
bind
arm
might
attribut
decreas
target
affin
case
potenti
toxic
side
effect
might
also
aris
review
see
levin
introduct
methylphosphon
deoxyribozym
backbon
increas
rel
hydrophob
eas
diffus
across
membran
shoji
et
al
introduct
two
end
four
rna
monom
endblock
deoxyribozym
twofold
sixfold
increas
respect
origin
cleavag
rate
obtain
warashina
et
al
schubert
et
al
ribonucleotid
contain
methylen
bridg
connect
ribos
review
see
orum
wengel
incorpor
lock
nucleic
acid
lna
bind
arm
improv
hybrid
potenti
sever
dna
enzym
enhanc
fold
catalyt
loop
vester
et
al
induc
conform
chang
toward
atyp
helix
bondensgaard
et
al
sioud
leirdal
introduc
thymidin
deoxyribozym
achiev
sixfold
increas
stabil
sustain
cleavag
activ
wherea
other
sun
et
al
observ
tenfold
enhanc
serum
stabil
combin
arm
length
deoxyribozym
sun
et
al
shown
invert
thymidin
influenc
cleavag
rate
rang
slight
loss
effici
fourfold
increas
activ
contrast
schubert
et
al
abl
confirm
observ
modif
deoxyribozym
fig
increas
catalyt
activ
less
common
list
phosphoramid
phosphoramid
np
modif
show
increas
twofold
rel
effici
deoxyribozym
translat
initi
region
influenza
viru
takahashi
et
al
adenosin
bind
regul
bind
deoxyribozym
target
mrna
regul
oligonucleotid
adenosin
adodnazym
adenosin
alon
adodnazym
ii
requir
fig
ad
adenosin
adodnazym
catalysi
deoxyribozym
increas
wang
et
al
intercal
tether
intercal
anthraquinon
tanth
tether
via
dthreoninol
directli
amid
bond
posit
bind
arm
ii
eightfold
increas
activ
obtain
asanuma
et
al
modif
focus
catalyt
core
deoxyribozym
core
sensit
chang
preserv
particular
posit
fig
highli
conserv
substitut
base
lead
complet
loss
catalyt
activ
known
except
nucleotid
replac
posit
least
conserv
base
n
c
g
anoth
posit
natur
occur
nucleotid
substitut
possibl
posit
posit
without
sever
effect
joyc
zaborowska
et
al
result
one
conclud
nucleotid
posit
directli
involv
form
catalyt
center
curious
schubert
et
al
demonstr
modif
group
posit
interfer
correct
fold
catalyt
centr
even
doubl
origin
valu
catalyt
rate
final
alter
deoxyribozym
size
nucleotid
long
chemistri
affect
degre
uptak
cell
cultur
dass
et
al
intern
deoxyribozym
need
support
electropor
transfect
infect
spite
uptak
modifi
singlestrand
dna
molecul
wide
investig
mechanist
aspect
refus
give
secret
dna
molecul
associ
cell
membran
intern
cytoplasm
cell
surfac
receptor
yakubov
et
al
gp
stein
et
al
involv
protein
kinas
c
pkc
unspecif
use
freerid
via
receptormedi
endocytosi
altern
pinocytosi
absorpt
endocytosi
might
also
play
import
role
oligonucleotid
odn
uptak
patil
et
al
mechan
use
depend
factor
odn
chemistri
length
conform
concentr
cell
type
stage
cell
cycl
degre
cell
differenti
intracellular
condit
cell
environ
eg
ph
cation
concentr
akhtar
et
al
henc
univers
mechan
conclus
explain
intern
process
identifi
uptak
label
dna
molecul
appear
characterist
punctat
cytoplasm
distribut
loke
et
al
grimp
silver
fate
dna
molecul
depend
local
either
endosom
lysosom
lysosom
membran
contain
proton
hydrogen
pump
chang
insid
ph
condit
promot
acid
hydrolysi
also
activ
lysosom
enzym
rapidli
degrad
odn
contrast
endosom
keep
neutral
ph
lumen
degrad
odn
occur
henc
odn
readi
work
way
dna
molecul
escap
lysosom
endosom
unclear
like
mechan
penetr
compart
conform
chang
membran
protein
destabil
membran
occur
bacteri
toxin
farahbahksch
et
al
virus
white
et
al
releas
cytoplasm
dna
molecul
report
becom
local
predominantli
cytoplasm
within
nucleu
zamecnik
stephenson
cerruzi
et
al
chin
et
al
leonetti
et
al
conclus
mention
made
special
care
taken
select
cell
investig
oftenobserv
problem
encount
util
clone
cell
line
use
deoxribozym
knockdown
agent
frequent
cell
line
show
limit
uptak
agent
wherea
primari
cell
show
good
excel
intern
concern
cn
author
success
use
hippocamp
slice
cultur
grimp
silver
primari
astrocyt
grimp
silver
primari
retin
ganglion
cell
rie
et
al
high
effici
intern
deoxyribozym
schwann
cell
pn
also
exhibit
high
effici
grimp
et
al
wherea
dorsal
root
ganglion
cell
fail
intern
deoxyribozym
data
shown
clone
cell
line
aid
transfect
reagent
electropor
infect
necessari
intern
wherea
primari
cell
need
enhanc
techniqu
use
primari
cell
uptak
odn
howev
increas
laboratori
newli
interest
research
field
probabl
make
mistak
initi
select
wrong
cell
type
experi
lack
effect
agent
observ
simpl
administr
chemic
stabil
deoxyribozym
salin
solut
led
effici
uptak
biolog
effect
vivo
find
point
unknown
uptak
mechan
occur
insid
organ
encount
cell
cultur
yet
schubert
kurreck
circumv
problem
li
et
al
use
singlestrand
dna
express
vector
gener
deoxyribozym
control
two
separ
promot
base
catalyt
effici
compar
natur
occur
ribozym
deoxyribozym
appli
vivo
inactiv
target
mrna
molecul
santoro
joyc
effici
nearcatalyt
perfect
consist
alberi
knowl
definit
reaction
rate
limit
rate
diffusion
encount
enzym
substrat
alberi
knowl
therapeut
use
dnabas
rnabas
technolog
predic
absenc
group
phosphodiest
linkag
make
dna
stabl
hydrolysi
rna
physiolog
condit
li
breaker
word
halflif
unmodifi
deoxyribozym
human
serum
measur
h
compar
min
hammerhead
ribozym
schubert
kurreck
support
dnabas
technolog
come
find
dna
rna
duplex
tend
dissoci
easili
rna
rna
duplex
mean
mismatch
hybrid
arm
might
occur
bind
nontarget
mrna
inhibit
cleavag
activ
increas
dissoci
target
molecul
review
see
shaw
arya
furthermor
cleavag
rate
long
rna
molecul
sever
order
magnitud
lower
short
substrat
molecul
thomson
et
al
henc
deal
longsequ
target
like
biolog
system
deoxyribozym
activ
potenti
select
ribozym
tabl
show
deoxyribozym
investig
varieti
molecul
applic
neurolog
disord
howev
limit
two
compani
found
date
name
usbas
cytogenix
tan
et
al
germanybas
sterna
biolog
sel
et
al
test
deoxyribozym
type
preclin
trial
cancer
viral
infect
diseas
influenza
small
pox
hiv
asthma
research
wherea
cytogenix
gener
mammalian
singlestrand
dna
express
vector
deoxyribozym
express
call
syndna
sterna
biolog
administ
intranas
deoxyriboyzm
modifi
invert
fig
frequent
describ
investig
ribozym
therapeut
potenti
small
hammerhead
ribozym
birikh
et
al
follow
hairpin
ribozym
fig
ribozym
selfcleav
rna
rrna
interven
sequenc
tetrahymena
thermophila
kruger
et
al
rnase
p
guerriertakada
et
al
hepat
delta
viru
wu
et
al
transcript
neurospora
crassa
mitochondri
dna
plasmid
savil
collin
plant
pathogen
rna
viroid
satellit
rna
virusoid
diener
hammerhead
ribozym
requir
recognit
sequenc
nuh
cleavag
target
mrna
n
nucleotid
h
equal
c
u
cleavag
occur
u
h
jame
turner
contrast
hairpin
ribozym
sequenc
requir
bnguc
site
cleavag
b
equal
g
u
c
hampel
clinic
use
effort
made
reduc
number
nucleotid
bind
arm
within
catalyt
loop
structur
without
compromis
cleavag
abil
specif
hammerhead
ribozym
effici
cleavag
requir
nucleotid
wherea
crucial
respect
limit
number
nucleotid
long
also
contain
minimum
base
reduct
catalyt
loop
insert
dna
lead
chimer
miniribozym
minizym
fig
result
faster
cleavag
longer
rna
substrat
least
vitro
bind
arm
miniribozym
minizym
rather
length
around
nucleotid
hendri
et
al
actual
cleavag
reaction
ribozym
occur
suscept
linkag
lead
format
phosphodiest
hydroxyl
group
cech
similar
mechan
use
deoxyribozym
process
ribozym
requir
presenc
crystal
experi
reveal
assist
rna
fold
also
particip
directli
cleavag
mechan
dahm
uhlenbeck
pley
et
al
knockdown
technolog
frequent
use
last
two
decad
high
expect
therapeut
applic
plethora
public
focus
mechan
sirna
gene
silenc
deliveri
sirna
agent
therapeut
util
unwant
sideeffect
new
onlin
tool
provid
effect
design
algorithm
base
combin
mrna
target
sequenc
secondari
structur
sirna
duplex
endstabl
aim
minim
potenti
sequencedepend
offtarget
effect
propos
clinic
applic
rna
interfer
rnai
incorpor
chemic
synthes
sirna
duplex
twonucletotid
overhang
longer
sirna
nucleotid
use
lower
concentr
requir
silenc
target
agent
contain
asymmetr
overhang
two
nucleotid
one
blunt
end
recogn
dicer
process
amarzguioui
et
al
offtarget
effect
seem
avoid
complementari
region
sirna
local
within
open
read
frame
evad
untransl
region
review
see
jackson
linsley
elud
type
interferon
respons
doublestrand
rna
agent
longer
base
pair
doublestrand
singlestrand
rna
agent
via
tolllik
receptor
follow
immunostimulatori
sequenc
motif
avoid
hornung
et
al
judg
et
al
variou
deliveri
strategi
guid
therapeut
sirna
specif
locat
util
exampl
coupl
antibodi
fragment
song
et
al
aptam
mcnamara
et
al
packag
nanoparticl
coat
receptortarget
ligand
hulieskovan
et
al
wherebi
sirna
incorpor
endocytosi
modif
group
avoid
interferon
induct
morrissey
et
al
also
stagger
two
sirna
strand
seem
provid
optim
balanc
retent
rnai
potenc
protect
degrad
czauderna
et
al
summari
therapeut
target
sirna
agent
provid
koutsillieri
et
al
lare
et
al
light
success
achiev
sirna
invest
made
big
pharma
latest
decis
pharmaceut
industri
surpris
roch
close
three
r
facil
work
sirna
decemb
total
million
invest
previou
three
year
pfizer
abbott
announc
interest
technolog
novarti
also
show
reduc
enthusiasm
end
partnership
alnylam
end
howev
novarti
finish
program
includ
sirna
work
intern
pollak
schmidt
trailblaz
knockdown
agent
antisens
technolog
longtim
experi
techniqu
provid
necessari
foundat
design
efficaci
specif
odn
spite
size
odn
import
leav
littl
leeway
hardandfast
rule
rightsiz
odn
exist
henc
must
determin
empir
mean
odn
short
nucleotid
found
provid
good
discrimin
target
gene
express
wherea
case
long
odn
show
select
odn
short
select
long
access
tissu
difficult
work
control
odn
essenti
everi
experi
util
techniqu
henc
mismatch
odn
scrambl
antisens
sequenc
potenti
keep
gc
content
specif
work
counterpart
often
use
anoth
control
util
mix
base
odn
sens
sequenc
contain
scrambl
base
end
pure
sens
control
recommend
antisens
mechan
involv
natur
occur
gene
regul
fibroblast
growth
sens
antisens
transcript
form
doublestrand
rna
duplex
vivo
administr
sens
odn
antisens
transcript
one
gener
control
biolog
activ
produc
physiolog
effect
creat
confus
even
mislead
result
common
type
control
involv
random
revers
odn
first
obtain
mix
base
antisens
odn
latter
revers
antisens
sequenc
respect
orient
moreov
latter
unabl
hybrid
antisens
mrna
target
lesli
et
al
needless
say
essenti
analyz
antisens
control
sequenc
specif
blast
search
clinic
util
antisens
odn
st
crook
founder
chairman
ceo
isi
pharmaceut
compani
gener
first
food
drink
administr
fda
approv
antisens
drug
name
vitraven
target
cytomegaloviru
retin
hivposit
patient
eloqu
summar
pharmacokinet
antisens
pto
state
antisens
pto
readili
absorb
varieti
administr
rout
intramuscular
subcutan
intraderm
intraperiton
applic
pto
reach
maximum
plasma
concentr
within
min
distribut
occur
rapidli
broadli
peripher
tissu
accumul
drug
liver
kidney
without
cross
barrier
clearanc
antisens
pto
intern
cell
take
place
slowli
elimin
halflif
h
slow
metabol
halflif
h
test
organ
st
crook
colleagu
rm
crook
et
al
cossum
et
al
sand
et
al
agraw
et
al
observ
minim
differ
speci
differ
sequenc
abovedescrib
statement
thu
vivo
deliveri
antisens
pto
peripher
tissu
prove
rel
facil
conclus
crook
write
anim
human
perhap
surpris
antisens
pto
display
excel
parenter
pharmacokinet
properti
concentr
number
peripher
tissu
includ
liver
kidney
bone
marrow
skelet
muscl
skin
thu
special
drug
deliveri
system
requir
show
potent
vivo
activ
today
add
despit
earli
success
necessari
element
place
time
make
multipl
product
due
worldwid
shrinkag
drug
market
big
pharma
experienc
loss
billion
vitraven
discontinu
patient
group
small
raymond
warrel
chairman
ceo
genta
add
go
effect
singl
antisens
agent
attack
singl
gene
product
sure
target
absolut
central
role
complex
biolog
diseas
tri
treat
exampl
isi
drug
given
high
dose
sideeffect
modest
compar
anticanc
agent
fail
bad
choic
target
say
st
crook
signific
malign
look
jone
reviv
antisens
drug
observ
base
number
licens
big
pharmaceut
compani
distribut
last
two
year
pollak
target
specif
also
safe
treatment
requir
investig
liver
kidney
function
blood
analys
complet
blood
count
cbc
chemistri
furthermor
slow
administr
antisens
pto
particular
use
system
rout
essenti
safe
treatment
paradigm
summari
tabl
compar
advantag
disadvantag
deoxyribozym
technolog
abovement
knockdown
techniqu
present
clinic
studi
exist
sci
traumat
brain
injuri
wherea
recruit
studi
sirna
complet
activ
two
trial
ribozym
complet
activ
clinic
trial
complet
activ
base
antisens
technolog
found
fda
databas
wwwclinicaltrialsgov
lack
deoxyribozym
trial
demonstr
technolog
still
infanc
combin
sci
traumat
brain
injuri
one
knockdown
technolog
initi
basic
region
leucinezipp
transcript
factor
activ
doubl
phosphoryl
cjun
ntermin
kinas
jnk
within
transcript
activ
domain
jnk
one
three
gene
predominantli
found
cn
neuron
pyramid
neuron
subiculum
region
hippocampu
wherea
lower
level
identifi
heart
testi
maximum
activ
jnk
requir
phosphoryl
thr
tyr
residu
activ
loop
thr
residu
via
mitogenactiv
protein
kinas
kinas
phosphoryl
signific
increas
still
observ
contrast
phosphoryl
alon
induc
low
level
jnk
activ
addit
cjun
antiactiv
transcript
jun
b
jun
ip
davi
jnk
involv
neuron
differenti
apoptosi
neuron
diseas
alzheim
diseas
parkinson
diseas
stroke
pursu
sever
compani
cn
drug
indic
resnick
fennel
first
studi
util
deoxyribozym
cjun
demonstr
block
endotheli
cell
prolifer
migrat
inject
tumor
cell
vascular
endotheli
growth
factor
vegf
induc
neovascular
rat
cornea
melanoma
growth
inhibit
zhang
et
al
latest
discoveri
show
potent
induc
dass
et
al
transcript
factor
dass
et
al
base
offtarget
effect
molecul
involv
apoptot
process
wherea
class
addit
involv
mitosi
dna
replic
dna
damag
checkpoint
dna
repair
develop
differenti
analysi
shown
erk
akt
also
upregul
administr
dass
et
al
group
dass
choong
found
system
applic
repres
toxic
effect
blood
solid
tissu
adult
fetal
mice
slight
hepatotox
notic
mean
histolog
unlik
region
adult
brain
spinal
cord
hippocampu
possess
remark
capac
continu
axon
growth
reform
precis
synapt
connect
within
cn
inde
new
function
granul
neuron
lengthi
axon
gener
hippocampu
resid
popul
stemprogenitor
cell
throughout
adulthood
mani
speci
includ
human
grimp
et
al
describ
narrow
sickleshap
laminin
chain
pathway
begin
hilu
extend
along
pyramid
cell
bodi
layer
stratum
pyramid
stain
also
present
around
portion
apic
dendrit
closest
cell
bodi
stratum
lucidum
lack
entir
basal
distalmost
portion
apic
dendrit
young
pyramid
neuron
thu
laminin
stain
confin
strictli
within
stratum
pyramid
stratum
lucidum
provid
newli
gener
granul
neuron
growthpromot
guidanc
highway
mossi
axon
keef
nadel
amar
dent
identifi
ident
terrain
mossi
fiber
pathway
hippocamp
slice
cultur
mossi
fiber
show
abil
regener
lesion
region
howev
deoxyribozym
laminin
chain
administ
laminin
pathway
reduc
mossi
fiber
lose
abil
regener
instead
much
shorter
take
meander
cours
deoxyribozym
wash
laminin
immunoreact
return
mossi
fiber
regener
resum
grimp
et
al
last
decad
pg
identifi
ecm
molecul
particip
growth
inhibitori
environ
form
injuri
spinal
cord
whether
glycosaminoglycan
gag
chain
protein
core
prevent
regener
sever
axon
still
controversi
howev
prevent
initi
gagchain
begin
primarili
golgi
apparatu
hoffmann
et
al
increas
axon
growth
demonstr
moon
et
al
bradburi
et
al
golgi
apparatu
core
protein
pg
receiv
long
unbranch
gagsid
chain
chondroitin
sulfat
cs
dermatan
sulfat
ds
heparan
sulfat
hs
pg
special
link
tetrasaccharid
compos
xylos
galactos
galactos
glucuron
acid
linkmolecul
attach
serin
hydroxyl
side
chain
embed
specif
consensu
peptid
sequenc
core
protein
serv
primer
polysaccharid
growth
first
carbohydr
gagchain
name
xylos
udpxylos
catalyz
chaininiti
enzym
udpdxylosyltransfeas
et
al
furthermor
sugar
dglucuron
acid
glca
nacetyldgalactosamin
galnac
ad
specif
glycosyl
transferas
disaccharid
unit
individu
link
tetrasaccharid
still
golgi
compart
mani
polymer
sugar
coval
modifi
sequenti
coordin
seri
reaction
sulfat
posit
glca
andor
posit
galnac
residu
principl
pg
potenti
almost
limitless
heterogen
regard
number
type
gag
chain
attach
even
one
singl
type
core
protein
grimp
silver
local
administr
deoxyribozym
reduc
presenc
gag
chain
normal
creat
inhibitori
penumbra
around
epicent
spinal
cord
lesion
reduct
fulli
glycosyl
pg
allow
regener
microtranspl
adult
sensori
axon
around
beyond
central
core
lesion
result
confirm
hurtado
et
al
endogen
sever
sensori
axon
abl
enter
grow
spinal
cord
tissu
rostral
peripher
nerv
graft
deoxyribozym
treatment
untreat
spinal
cord
entri
growth
stall
base
enhanc
gagchain
synthesi
exampl
demonstr
deoxyribozym
success
reduc
mrna
protein
addit
number
deoxyribozym
provid
tabl
demonstr
applic
flourish
hope
neuroscientist
recogn
technolog
fruit
reward
altern
compar
establish
techniqu
three
phase
sci
typic
recogn
acut
phase
secondari
tissu
loss
chronic
phase
tator
immedi
mechan
damag
spinal
nervou
tissu
acut
phase
minut
day
cell
death
necrosi
barrag
action
potenti
spinal
shock
hemorrhag
swell
occur
lead
motor
function
restrict
loss
secondari
phase
minut
week
ischem
cell
death
electrolyt
shift
edema
continu
addit
lipid
peroxid
freerad
product
apoptosi
reactiv
gliosi
occur
within
h
neutrophil
invad
spinal
parenchyma
follow
lymphocyt
result
increas
cytokin
chemokin
contribut
loss
tissu
time
inhibitori
factor
pg
express
scar
gradual
matur
periles
site
chronic
phase
day
year
apoptosi
continu
addit
demyelin
caus
conduct
deficit
patient
tether
spinal
cord
occur
approxim
sci
patient
cyst
form
injuri
site
usual
continu
enlarg
syringomyelia
hulsebosch
start
farlow
et
al
sever
scientif
group
began
analyz
chang
gene
express
throughout
three
phase
variou
pn
cnstrauma
regener
model
present
day
wide
rang
differ
approach
perform
rather
special
question
investig
two
tempor
distinct
microgliarel
gene
cluster
byrn
et
al
analyz
effect
nmethyldaspart
receptor
inhibit
nesic
et
al
other
broader
question
summar
bareyr
schwab
spite
provid
import
new
insight
pathophysiolog
injur
spinal
cord
approach
common
rel
small
number
gene
select
investig
sheer
volum
data
creat
addit
challeng
dedic
softwar
databas
system
store
organ
microarray
data
imag
requir
descript
experiment
paramet
annot
via
miam
standard
normal
data
cluster
techniqu
proven
valuabl
requir
new
standard
statist
analysi
first
time
data
textmin
method
knearest
neighbor
classif
support
vector
machin
machin
learn
algorithm
neural
net
found
applic
field
kaiser
nisenbaum
combin
publish
data
set
five
differ
microarray
studi
examin
global
chang
nerv
tissu
gene
express
abl
extend
biolog
conclus
deriv
studi
next
logic
step
build
upon
exist
data
comprehend
complex
process
event
time
identifi
suitabl
target
molecul
design
new
deoxyribozym
prevent
regener
failur
therefor
essenti
collect
exist
inform
gene
protein
found
public
databas
connect
data
util
bioinformat
valid
computerbas
result
hypothesisdriven
experi
fig
provid
overal
pictur
sci
underli
biochem
pathway
potenti
protein
interact
lay
hand
sheer
number
appli
substanc
rie
et
al
written
preliminari
comput
program
suit
call
regener
data
mine
project
rdmp
build
insilico
protein
interact
model
draw
natur
languag
sourc
variou
databas
avail
onlin
larg
mysql
databas
provid
sequenc
interact
literatur
data
record
plu
queri
capabl
rdmp
abl
collect
identifi
gener
list
protein
involv
process
axon
growth
abstract
collect
pubm
classifi
medic
subject
head
mesh
term
nerv
regener
rie
et
al
mesh
control
vocabulari
maintain
nation
medic
librari
cover
subject
medic
domain
rdmp
recogn
protein
name
dictionaryrulebas
method
similar
egorov
et
al
dictionari
extract
def
field
univers
protein
resourc
uniprot
databas
emmert
et
al
list
english
stop
word
frequent
word
use
natur
languag
text
obtain
mysql
letter
alphabet
ad
exampl
tabl
illustr
method
main
step
approach
public
build
foundat
analysi
instead
microarray
databas
latter
contain
high
number
falseposit
falseneg
result
identifi
filter
wherea
review
process
journal
manuscript
assur
qualiti
data
prototyp
program
suit
grimp
colleagu
abl
identifi
protein
evalu
area
nerv
regener
time
classifi
use
gene
ontolog
term
protein
everi
field
biochemistri
found
list
rie
et
al
confirm
origin
hypothes
sci
base
complex
event
demonstr
challeng
one
face
modern
scienc
within
protein
indentifi
osteopontin
analysi
determin
novel
function
osteopontin
receptor
interact
neurit
outgrowth
retin
ganglion
cell
event
remain
elus
time
rie
et
al
continu
use
protein
seed
search
biomolecular
interact
network
databas
bind
author
abl
gener
proteinprotein
pp
interact
map
analyz
pp
interact
visual
cytoscap
fig
three
molecul
new
henc
uninvestig
field
sci
identifi
protein
protein
inhibitor
activ
stat
function
specif
inhibitor
transcript
factor
interact
nuclear
hormon
receptor
coregul
moilanen
et
al
kotaja
et
al
specif
sumo
ligas
cjun
schmidt
muller
review
see
shuai
liu
imoto
et
al
suppressor
regul
transform
growth
factor
tgf
activ
imoto
et
al
son
sevenless
so
interact
directli
mitogenactiv
protein
kinas
protein
seed
list
guanin
nucleotid
exchang
factor
boguski
mccormick
simon
et
al
function
regul
ra
activ
downward
knockout
result
embryon
lethal
mice
indic
essenti
function
mammalian
develop
wang
et
al
local
human
cell
contain
two
so
hso
gene
encod
close
relat
ubiquit
express
protein
chardin
mattei
normal
local
cell
cytosol
respons
growth
factor
stimul
recruit
plasma
membran
barsagi
one
public
marciano
et
al
describ
investig
among
other
so
hippocamp
apoptosi
traumat
brain
injuri
surfac
far
domain
fold
protein
conserv
secondari
structur
appear
critic
bind
ligand
rather
primari
structur
feng
et
al
yu
et
al
function
signal
transduct
review
see
pawson
cell
polar
chenevert
et
al
enzymat
activ
leto
et
al
volpp
et
al
transcript
regul
bustelo
et
al
giachino
et
al
limb
morphogenesi
chan
et
al
real
time
quantit
pcr
injur
spinal
cord
normal
reveal
so
express
peak
h
contus
wherea
peak
occur
h
fig
none
protein
investig
regard
potenti
function
sci
spite
import
demonstr
exampl
neuron
develop
furthermor
prototyp
program
suit
enabl
author
rank
protein
base
number
public
tabl
gener
list
project
polit
import
respect
protein
direct
favor
regener
commun
order
comprehend
process
trauma
rather
scientif
import
nevertheless
scientif
inform
receiv
select
extens
studi
protein
still
import
fit
togeth
piec
puzzl
regener
failur
deoxyribozym
great
potenti
serv
knockdown
agent
varieti
neurobiolog
problem
therapeut
purpos
easi
administr
reliabl
specif
low
product
cost
use
thought
within
limit
technolog
especi
suitabl
vivo
approach
manipul
environ
injur
spinal
cord
brain
tissu
combin
bioinformat
approach
indentifi
suitabl
lesswellstudi
target
molecul
way
pave
better
comprehens
mechan
lead
regener
failur
axon
cn
trauma
ultim
find
treatment
paralysi
